.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
McKinsey
Cerilliant
Medtronic
Citi
Merck
US Department of Justice
Baxter
Daiichi Sankyo
McKesson

Generated: December 14, 2017

DrugPatentWatch Database Preview

Pfizer Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER PHARMS, and when can generic versions of PFIZER PHARMS drugs launch?

PFIZER PHARMS has seven approved drugs.

There are two US patents protecting PFIZER PHARMS drugs.

There are fifteen patent family members on PFIZER PHARMS drugs in sixteen countries and nine supplementary protection certificates in six countries.

Summary for Pfizer Pharms

International Patents:15
US Patents:2
Tradenames:6
Ingredients:6
NDAs:7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Pfizer PharmsACCURETIChydrochlorothiazide; quinapril hydrochlorideTABLET;ORAL020125-003Dec 28, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer PharmsREZULINtroglitazoneTABLET;ORAL020720-003Aug 4, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer PharmsREZULINtroglitazoneTABLET;ORAL020720-002Jan 29, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer PharmsLOPIDgemfibrozilTABLET;ORAL018422-003Nov 20, 1986ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer PharmsNITROSTATnitroglycerinTABLET;SUBLINGUAL021134-002May 1, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer PharmsNEURONTINgabapentinCAPSULE;ORAL020235-001Dec 30, 1993ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer PharmsNEURONTINgabapentinCAPSULE;ORAL020235-002Dec 30, 1993ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer PharmsNITROSTATnitroglycerinTABLET;SUBLINGUAL021134-001May 1, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer PharmsACCUPRILquinapril hydrochlorideTABLET;ORAL019885-003Nov 19, 1991ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer PharmsREZULINtroglitazoneTABLET;ORAL020720-001Jan 29, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pfizer Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer PharmsACCUPRILquinapril hydrochlorideTABLET;ORAL019885-001Nov 19, 1991► Subscribe► Subscribe
Pfizer PharmsACCUPRILquinapril hydrochlorideTABLET;ORAL019885-001Nov 19, 1991► Subscribe► Subscribe
Pfizer PharmsREZULINtroglitazoneTABLET;ORAL020720-002Jan 29, 1997► Subscribe► Subscribe
Pfizer PharmsNEURONTINgabapentinCAPSULE;ORAL020235-002Dec 30, 1993► Subscribe► Subscribe
Pfizer PharmsACCUPRILquinapril hydrochlorideTABLET;ORAL019885-002Nov 19, 1991► Subscribe► Subscribe
Pfizer PharmsREZULINtroglitazoneTABLET;ORAL020720-001Jan 29, 1997► Subscribe► Subscribe
Pfizer PharmsACCURETIChydrochlorothiazide; quinapril hydrochlorideTABLET;ORAL020125-002Dec 28, 1999► Subscribe► Subscribe
Pfizer PharmsACCURETIChydrochlorothiazide; quinapril hydrochlorideTABLET;ORAL020125-002Dec 28, 1999► Subscribe► Subscribe
Pfizer PharmsNEURONTINgabapentinCAPSULE;ORAL020235-003Dec 30, 1993► Subscribe► Subscribe
Pfizer PharmsACCURETIChydrochlorothiazide; quinapril hydrochlorideTABLET;ORAL020125-001Dec 28, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PFIZER PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
nitroglycerinSublingual Tablets0.6 mgNITROSTAT12/29/2011
nitroglycerinSublingual Tablets0.3 mg, 0.4 mg and 0.6 mgNITROSTAT10/19/2005

International Patent Family for Pfizer Pharms Drugs

Country Document Number Estimated Expiration
Austria209911► Subscribe
South Korea100569763► Subscribe
Japan2001518500► Subscribe
Portugal1019039► Subscribe
Spain2169558► Subscribe
New Zealand502878► Subscribe
TaiwanI228989► Subscribe
Australia9489398► Subscribe
Canada2299231► Subscribe
Israel134395► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pfizer Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
C/GB97/084United Kingdom► SubscribePRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Baxter
Johnson and Johnson
Fish and Richardson
Boehringer Ingelheim
Federal Trade Commission
Moodys
Chubb
Farmers Insurance
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot